公开(公告)号：AU690273B2

公开(公告)日：1998-04-23

申请号：AU2491697

申请日：1997-06-17

Applicant: MITSUI TOATSU CHEMICALS

Inventor： IKEDA ICHIRO ,  KONO NAOKO ,  MAKINO TADASHI ,  HASHIMOTO YOSHIHIDE

IPC: C07K16/26 ,  G01N33/543 ,  G01N33/74 ,  G01N33/577

Abstract: A monoclonal antibody specifically reactive to a human growth hormone with a molecular weight of about 20,000, a cell line capable of producing the monoclonal antibody and an immunoassay of a human growth hormone having a molecular weight of about 20,000 using the monoclonal antibody. An animal cell capable of producing an antibody specific to a human growth hormone having a molecular weight of 20,000 (20k hGH) was prepared from an animal immunized with 20k hGH. The animal cell was fused with a myeloma cell to produce a monoclonal antibody which specifically reacted to 20k hGH, but substantially not to 22k hGH. The monoclonal antibody was useful for immunoassay of 20k hGH.

公开(公告)号：DE3885735T2

公开(公告)日：1994-07-07

申请号：DE3885735

申请日：1988-08-22

Applicant: MITSUI TOATSU CHEMICALS

Inventor： MURAMATSU TAKASHI ,  MURAMATSU HISAKO ,  INOUE HIROSHI ,  AWAYA AKIRA ,  FUKUI HIDEO ,  HASHIMOTO YOSHIHIDE

IPC: C12P21/08 ,  A61K35/30 ,  A61K35/54 ,  A61K38/00 ,  A61P25/00 ,  A61P35/00 ,  A61P43/00 ,  C07K1/16 ,  C07K1/22 ,  C07K14/42 ,  C07K14/435 ,  C07K14/47 ,  C07K16/00 ,  C07K16/18 ,  C07K16/30 ,  C12N5/10 ,  C12N5/12 ,  C12N5/20 ,  C12N15/02 ,  C12R1/91 ,  G01N33/53 ,  G01N33/574 ,  G01N33/68 ,  G01N33/74 ,  C07K15/06 ,  A61K39/00 ,  A61K39/395 ,  C07K3/20 ,  C07K15/04 ,  C12N5/00 ,  C12N15/00 ,  C12P21/00 ,  G01N33/577

公开(公告)号：DE3885735D1

公开(公告)日：1993-12-23

申请号：DE3885735

申请日：1988-08-22

Applicant: MITSUI TOATSU CHEMICALS

Inventor： MURAMATSU TAKASHI ,  MURAMATSU HISAKO ,  INOUE HIROSHI ,  AWAYA AKIRA ,  FUKUI HIDEO ,  HASHIMOTO YOSHIHIDE

IPC: C12P21/08 ,  A61K35/30 ,  A61K35/54 ,  A61K38/00 ,  A61P25/00 ,  A61P35/00 ,  A61P43/00 ,  C07K1/16 ,  C07K1/22 ,  C07K14/42 ,  C07K14/435 ,  C07K14/47 ,  C07K16/00 ,  C07K16/18 ,  C07K16/30 ,  C12N5/10 ,  C12N5/12 ,  C12N5/20 ,  C12N15/02 ,  C12R1/91 ,  G01N33/53 ,  G01N33/574 ,  G01N33/68 ,  G01N33/74 ,  C07K15/06 ,  A61K39/00 ,  A61K39/395 ,  C07K3/20 ,  C07K15/04 ,  C12N5/00 ,  C12N15/00 ,  C12P21/00 ,  G01N33/577

公开(公告)号：EP0814091A2

公开(公告)日：1997-12-29

申请号：EP97304247

申请日：1997-06-17

Applicant: MITSUI TOATSU CHEMICALS

Inventor： IKEDA ICHIRO ,  KONO NAOKO ,  MAKINO TADASHI ,  HASHIMOTO YOSHIHIDE

IPC: C07K16/26 ,  G01N33/543 ,  G01N33/74 ,  C07K17/00 ,  C12N5/20 ,  G01N33/577

CPC classification number: C07K16/26 ,  G01N33/54306 ,  G01N33/74 ,  G01N2333/61 ,  Y10S530/809

Abstract: A monoclonal antibody specifically reactive to a human growth hormone with a molecular weight of about 20,000, a cell line capable of producing the monoclonal antibody and an immunoassay of a human growth hormone having a molecular weight of about 20,000 using the monoclonal antibody. An animal cell capable of producing an antibody specific to a human growth hormone having a molecular weight of 20,000 (20k hGH) was prepared from an animal immunized with 20k hGH. The animal cell was fused with a myeloma cell to produce a monoclonal antibody which specifically reacted to 20k hGH, but substantially not to 22k hGH. The monoclonal antibody was useful for immunoassay of 20k hGH.

Abstract translation: 一种单克隆抗体，与分子量为约20,000，一个细胞系能够产生单克隆抗体的人生长激素特异性反应和免疫测定使用单克隆抗体具有约20000的分子量的人生长激素。 动物细胞能够在特定的具有20,000（20k hGH的）的分子量，其从与20k hGH的免疫的动物制备的人生长激素抗体产生的。 动物细胞有什么骨髓瘤细胞融合以产生单克隆抗体具体在哪些的反应是20k hGH的，但基本上不22KhGH的。 单克隆抗体，其为20KhGH的免疫测定法是有用的。

公开(公告)号：EP0331743A4

公开(公告)日：1990-06-27

申请号：EP88907375

申请日：1988-08-22

Applicant: MITSUI TOATSU CHEMICALS

Inventor： MURAMATSU TAKASHI ,  MURAMATSU HISAKO ,  INOUE HIROSHI ,  AWAYA AKIRA ,  FUKUI HIDEO ,  HASHIMOTO YOSHIHIDE

IPC: C12P21/08 ,  A61K35/30 ,  A61K35/54 ,  A61K38/00 ,  A61P25/00 ,  A61P35/00 ,  A61P43/00 ,  C07K1/16 ,  C07K1/22 ,  C07K14/42 ,  C07K14/435 ,  C07K14/47 ,  C07K16/00 ,  C07K16/18 ,  C07K16/30 ,  C12N5/10 ,  C12N15/02 ,  C12R1/91 ,  G01N33/53 ,  G01N33/574 ,  G01N33/68 ,  G01N33/74

CPC classification number: G01N33/6893 ,  A61K38/00 ,  C07K14/4715 ,  C07K14/70503 ,  C07K16/18 ,  C07K16/30 ,  G01N33/57476 ,  G01N33/74

公开(公告)号：JPH0477438A

公开(公告)日：1992-03-11

申请号：JP18947690

申请日：1990-07-19

Applicant: MITSUI TOATSU CHEMICALS

Inventor： AWAYA AKIRA ,  HASHIMOTO YOSHIHIDE ,  FUKUI HIDEO ,  KOJIMA SHUJI

IPC: G01N33/53 ,  A61K49/00 ,  A61K51/00 ,  A61P35/00 ,  C07K16/28 ,  G01N33/574

Abstract: PURPOSE:To provide a labeled anti-GP68 antibody especially useful for the diagnosis and treatment of cancer, etc., and containing an antibody (anti-GP68 antibody) against GP68 sialoglycoprotein originated from mouse fetus and a labeling compound bonded to the antibody. CONSTITUTION:The objective antibody can be produced by bonding (A) an anti-GP68 antibody prepared by conventional process from antiserum of an animal immunized with GP68, a supernatant fluid of cultured hybridoma capable of producing anti-GP68 monoclonal antibody or ascites of an animal transplanted with the above hybridoma and (B) a labeling compound through a direct bond, a chelate compound, a crosslinking agent or a complex-forming compound. The labeling compound is e.g. radioactive isotope, a fluorescent pigment (e.g. fluorescein isothiocyanate), a sensitizer (e.g. porphyrin compound) and a magnetic material (e.g. a paramagnetic metal such as Mn, Fe and Cu). The antibody has high specific accumulation property to a cancer site, enables improved specific and selective imaging of the cancer site in a short time after administration and exhibits antitumor effect by the targeting of cancer.

公开(公告)号：JPH06340526A

公开(公告)日：1994-12-13

申请号：JP13185393

申请日：1993-06-02

Applicant: MITSUI TOATSU CHEMICALS

Inventor： HASHIMOTO YOSHIHIDE ,  MIYAMA YUKIO ,  MIZUCHI AKIRA ,  FUKAZAWA NOBUYUKI

IPC: A61K31/12 ,  A61K31/122 ,  A61K31/215 ,  A61P3/08 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P25/02 ,  A61P25/28 ,  A61P43/00

Abstract: PURPOSE:To obtain an agent for inducing the production and secretion of nerve growth factor(NGF), exhibiting remarkable inducing effect at a low concentration and expectable as an agent for the prevention and treatment of various cerebral function disorders and peripheral nerve disorders. CONSTITUTION:The agent for inducing the production and secretion of NGF contains a substituted 1,4-naphthoquinone derivative of the formula [R1 to R4 are H, halogen or (substituted)alkyl or alkenyl; X1 and X2 are OH which may be esterified or etherified], e.g. 5,8-dihydroxy-1,4-naphthoquinone or 2,3- dichloro-5,8-dihydroxy-1,4-naphthoquinone, as an active component. The diseases to be treated or prevented by this agent for inducing the production and secretion of NGF are ischemic cerebral diseases, Alzheimer's disease, diabetes, familial dysautonomia, neurofibromatosis, neuroblastoma, chromaffinoma, etc.

公开(公告)号：JPH03173899A

公开(公告)日：1991-07-29

申请号：JP20569088

申请日：1988-08-20

Applicant: MITSUI TOATSU CHEMICALS ,  MITSUI PHARMACEUTICALS ,  MURAMATSU TAKASHI

Inventor： MURAMATSU TAKASHI ,  MURAMATSU TOSHIKO ,  INOUE HIROSHI ,  AWAYA AKIRA ,  FUKUI HIDEO ,  HASHIMOTO YOSHIHIDE

IPC: C12P21/08 ,  A61K35/30 ,  A61K35/54 ,  A61K38/00 ,  A61P25/00 ,  A61P35/00 ,  A61P43/00 ,  C07K1/16 ,  C07K1/22 ,  C07K14/42 ,  C07K14/435 ,  C07K14/47 ,  C07K16/00 ,  C07K16/18 ,  C07K16/30 ,  C12N5/10 ,  C12N5/12 ,  C12N5/20 ,  C12N15/02 ,  C12R1/91 ,  G01N33/53 ,  G01N33/574 ,  G01N33/68 ,  G01N33/74

Abstract: NEW MATERIAL:A protein 68000 in molecular weight and 5.4-5.6 in isoelectric point, specifically found in the organism ranging from fertilized one to one- week-old one. USE:A therapeutic or preventive agent for the diseases due to brain and nervous system aberrations, the aplasia or hyperplasia of various organs and tissues and cancer, etc. A diagnostic agent for these diseases. PREPARATION:Firstly, a liquid extract from the tissue or cells of organism ranging from fertilized one to one-week-old one (e.g. mouse fetal brain) is brought into contact with a carrier with lectin carried as affinity reagent. Thence, from the components adsorbed to said carrier, the objective protein is selectively eluted and isolated using, as eluting solution, e.g. a 0.01-0.2 M lactose solution.